Floatz logo

(3RS)-1-(6-(.ALPHA.-METHYLPOLY(OXYETHYLENE)AMINO)-6-OXOHEXYL)-2,5-DIOXOPYRROLIDIN-3-YL)-L-CYSTEINAMIDE, (20000 MW)

Breast Cancer

Lumicell, Inc.OtherPhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
59/ 100

Competitive context

891 Active assets in the Breast Cancer cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
ERIBULIN MONOMETHANESULFONATE
Henan Cancer Hospital
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB

View all 50 →

Same molecule, other indications

(3RS)-1-(6-(.ALPHA.-METHYLPOLY(OXYETHYLENE)AMINO)-6-OXOHEXYL)-2,5-DIOXOPYRROLIDIN-3-YL)-L-CYSTEINAMIDE, (20000 MW) is also rated in:

Neoadjuvant TherapyDormant
CC
Indicative ·
46 / 100
View asset →
Peritoneal MetastasesDormant
CC
Indicative ·
45 / 100
View asset →
Neoplasm, ResidualDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →